Bio-Techne AI Stock Analysis
Want to see TECH full AI Analyst Report?
Bio-Techne (TECH) AI Stock Analysis
Bio-Techne
(NASDAQ:TECH)
The score is driven primarily by strong financial quality (healthy margins, low leverage, and strong free cash flow), supplemented by a constructive technical trend and a favorable M&A catalyst that improves near-term outcome visibility. These positives are meaningfully offset by expensive valuation (high P/E and low dividend yield), which limits upside without continued execution.
Bio-Techne Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down sales across regions so you can see where the company’s demand is strongest and where it faces exposure to local economic cycles, regulatory changes, or currency swings. Helps gauge geographic diversification and where future growth or risk is concentrated.
Bio-Techne's revenue growth in the United States and EMEA regions remains robust, reflecting strong demand in biopharma markets. Greater China shows signs of recovery with low double-digit growth, aligning with earnings call optimism about stabilization. However, the Rest of World and UK regions face challenges, possibly due to geopolitical and funding uncertainties. The strategic divestiture of Exosome Diagnostics is expected to enhance margins, supporting future profitability despite current market uncertainties.
Bio-Techne (TECH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $11.41B
- Dividend Yield
- 0.55%
- Average Volume (3M)
- 2.89M
- Price to Earnings (P/E)
- 66.1
- Beta (1Y)
- 0.84
- Revenue Growth
- 0.94%
- EPS Growth
- 122.38%
- Country
- US
- Employees
- 3,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Bio-Techne Business Overview & Revenue Model
Company Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments,...
How the Company Makes Money
Bio-Techne makes money primarily by selling life-science research and diagnostic products and, to a lesser extent, associated services. Key revenue streams include: (1) Consumable reagents used repeatedly in lab workflows—such as recombinant proteins...
Bio-Techne Earnings Call Summary
The call highlighted strong execution in high-value growth vectors (Spatial Biology/COMET, GMP proteins excl. timing impacts, Proteomic Analysis instruments, large pharma strength and four consecutive quarters of China growth), solid sequential margin improvement and robust cash generation. Offsetting these positives were a 2% organic revenue decline, continued weakness in emerging/early-stage biotech spending, timing headwinds from two fast-track cell therapy customers and an OEM order, and YoY mix-related margin pressure. Management expects near-term organic revenue to be roughly flat but positions the business for an inflection in fiscal 2027 as funding improvements translate to customer spending.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Bio‑Techne said it expects Q4 organic revenue to be approximately flat, with underlying growth across the rest of the portfolio running at low single digits once the company‑specific GMP/cell‑therapy timing headwind (which will moderate to ~150 basis points in Q4 and be fully lapped in FY‑2027) is excluded; management also reiterated that the prior quarter suffered a ~400‑bp timing headwind, that biotech funding has rebounded (+90% and +50% in recent fiscal Q2 and Q3) with a typical 2–3 quarter lag to spending, and that they intend to expand Q4 margins by roughly 100 basis points year‑over‑year (building on Q3 adjusted operating margin of 34.2%, a 310‑bp sequential improvement, and adjusted gross margin of 70.4%); longer term they said they would be disappointed if FY‑2027 did not deliver at least mid‑single‑digit growth as company‑specific headwinds roll off and funding translates to customer spend.
Bio-Techne Financial Statement Overview
Summary
Strong overall fundamentals supported by solid profitability (TTM gross margin ~66%, operating margin ~16%, EBITDA margin ~25%), conservative leverage (TTM debt-to-equity ~0.13), and robust/free-cash-flow generation (TTM FCF ~$308M). The main risk is uneven year-to-year profitability/returns and slightly weaker recent cash-flow coverage versus prior annual periods, suggesting some sensitivity to mix/timing.
Income Statement
76PositiveBalance Sheet
84Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.23B | 1.22B | 1.22B | 1.16B | 1.14B | 1.11B |
| Gross Profit | 807.58M | 799.07M | 790.27M | 769.73M | 769.82M | 756.50M |
| EBITDA | 328.77M | 343.44M | 216.88M | 313.14M | 457.11M | 413.76M |
| Net Income | 171.97M | 181.86M | 73.40M | 168.10M | 285.26M | 272.05M |
Balance Sheet | ||||||
| Total Assets | 2.64B | 2.59B | 2.56B | 2.70B | 2.64B | 2.29B |
| Cash, Cash Equivalents and Short-Term Investments | 351.13M | 264.71M | 162.19M | 152.86M | 204.31M | 247.03M |
| Total Debt | 285.56M | 289.09M | 444.06M | 419.54M | 454.96M | 325.97M |
| Total Liabilities | 471.13M | 478.50M | 639.06M | 635.02M | 672.18M | 593.79M |
| Stockholders Equity | 2.17B | 2.11B | 1.92B | 2.07B | 1.97B | 1.70B |
Cash Flow | ||||||
| Free Cash Flow | 308.20M | 263.22M | 256.55M | 236.10M | 216.15M | 280.36M |
| Operating Cash Flow | 337.60M | 292.07M | 287.56M | 298.98M | 254.39M | 325.27M |
| Investing Cash Flow | -22.72M | -18.19M | -35.18M | -203.03M | -265.65M | -96.85M |
| Financing Cash Flow | -108.53M | -169.11M | -253.91M | -122.40M | 22.62M | -242.85M |
Bio-Techne Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Positive. The current price of 72.75 is above the 20-day moving average (MA) of 72.64, above the 50-day MA of 72.47, and above the 200-day MA of 63.31, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 52.22 is Neutral, neither overbought nor oversold. The STOCH value of 48.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TECH.
Bio-Techne Risk Analysis
Bio-Techne disclosed 31 risk factors in its most recent earnings report. Bio-Techne reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBio-Techne Peers Comparison
Overall Rating
TECH74Outperform
ADPT64Neutral
ABCL57Neutral
ABSI50Neutral
MRVI48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | $11.41B | 66.08 | 8.22% | 0.55% | 0.94% | 122.38% | |
| 64Neutral | $4.61B | -62.93 | -37.40% | ― | 17.91% | 16.01% | |
| 57Neutral | $3.60B | -23.08 | -15.35% | ― | 92.10% | 16.43% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.31B | -9.50 | -60.84% | ― | -47.18% | 12.12% | |
| 48Neutral | $1.89B | -16.31 | -31.86% | ― | 10.77% | 46.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TECH | Bio-Techne | 72.75 | 14.34 | 24.54% | |
| ADPT | Adaptive Biotechnologies | 28.46 | 12.14 | 74.39% | |
| MRVI | Maravai Lifesciences Holdings, Inc. | 7.38 | 3.96 | 115.79% | |
| ABCL | Abcellera Biologics, Inc. | 11.02 | 7.61 | 223.17% | |
| ABSI | Absci Corp. | 8.18 | 5.41 | 195.31% | |
| KLRA | Kailera Therapeutics, Inc. | 11.79 | -14.21 | -54.65% |
Bio-Techne Corporate Events
Bio-Techne Declares Quarterly Dividend Amid Merck Transaction
NeutralOn November 3, 2026, Bio-Techne said its board had decided to pay a $0.08-per-share dividend for the quarter ended September 30, 2026. The dividend was scheduled for November 23 to shareholders of record on November 13, provided the company’s transac...
Bio-Techne Shareholders Approve Merck Acquisition Agreement
PositiveOn September 23, 2026, Bio-Techne shareholders approved the Agreement and Plan of Merger under which Merck KGaA, Darmstadt, Germany will acquire the company, following a special meeting where 78.55% of eligible shares were represented and the merger...
Bio-Techne Supplements Merger Proxy Amid Shareholder Litigation
NeutralBio-Techne Corporation, a Minnesota-based life sciences tools and diagnostics provider, supplies specialized reagents, instruments and analytical technologies to biopharma, academic and clinical customers worldwide. Its portfolio underpins drug disco...
Bio-Techne reports stronger profitability in fiscal Q4 2026
PositiveBio-Techne reported fourth-quarter fiscal 2026 results on August 12, 2026, showing modest top-line growth but stronger profitability, as organic revenue rose 3% to $321.2 million while GAAP EPS swung to $0.35 from a loss a year earlier and full-year...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
